---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-042352"
form_type: "8-K"
ticker: "GRCE"
cik: "0001444192"
company_name: "Grace Therapeutics, Inc."
filed_at: "2024-09-30T23:59:59+00:00"
generated_at: "2026-05-31T00:39:45.680773+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Acasti Pharma shareholders approve continuance to BC, domestication to Delaware, and 2024 equity plan

## Summary
- Shareholders approved continuance from Quebec to British Columbia (5,874,491 For, 71,931 Against, 8,683 Abstain).
- Shareholders approved domestication from British Columbia to Delaware (5,891,584 For, 54,366 Against, 9,155 Abstain).
- Shareholders approved the 2024 Equity Incentive Plan (5,832,903 For, 86,289 Against, 35,913 Abstain).
- All five director nominees were elected; KPMG ratified as auditor (7,055,362 For).
- Advisory vote on named executive officer compensation passed (5,685,429 For, 98,138 Against).

## SEC filing metadata
- accession: 0001140361-24-042352
- form_type: 8-K
- ticker: GRCE
- cik: 0001444192
- company_name: Grace Therapeutics, Inc.
- filed_at: 2024-09-30T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1444192/000114036124042352/0001140361-24-042352-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1444192/000114036124042352/ef20036442_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-042352
- JSON: https://secwatch.observer/filing/0001140361-24-042352.json
- Plain text: https://secwatch.observer/filing/0001140361-24-042352.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.